The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
The latest report by IMARC, titled “
PremenstrualSyndromeTreatmentMarket:GlobalIndustryTrends,Share,Size,Growth,Opportunity andForecast2023-2028
” " finds that the global online gambling market size reached US$ 1,346 Million in 2022.
Premenstrual syndrome (PMS) treatment involves therapeutic processes to alleviate emotional, physical, and psychological symptoms that women experience, including bloating, breast tenderness, body pain, fatigue, mood swings, and anxiety. These symptoms occur at the end of the luteal phase and subside with menstruation or shortly thereafter. They are often treated by antidepressants, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, ovarian suppression agents, and hormonal contraceptives, which are available over the counter or via prescription. Additionally, novel PMS treatments, including topical gels, creams, capsules, and suppositories, are also used to manage mood imbalances, reduce uterine cramps, and promote muscle relaxation.
Request Free Sample Report:
https://www.imarcgroup.com/premenstrual-syndrome-treatment-market/requestsample
The market is primarily driven by the increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) due to sedentary lifestyles and hectic working schedules of the female working population. In addition, rising awareness among individuals regarding available treatment solutions for PMS disorders represents another major growthinducing factor. Besides this, individuals are adopting nutritional supplements made with plant-based sources to provide relief from PMS.
These supplements contain nutrients, such as calcium, potassium, magnesium, and proteins, that aid in reducing fatigue and easing anxiety and depression. This, coupled with the introduction of smartphone applications that records physiological and emotional changes occurring in the body and sends notification reminders for medication, is positively influencing the market growth. Moreover, the launch of advanced medications with minimal side effects that aid in maintaining the appropriate pH balance in the body is also creating a favorable market outlook. Looking forward, IMARC Group expects the market value to reach US$ 1,683 Million by 2028, exhibiting a CAGR of 3.9% during 2023-2028.
Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).
MarketSummary:
BreakupbyDrugType:
• Analgesics
• Antidepressants
• Oral Contraceptives and Ovarian Suppression Agents
• Others
BreakupbyType:
• Prescription
• Over-the-Counter
BreakupbyDistributionChannel:
• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Stores
BreakupbyRegion:
• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
CompetitiveLandscapewithKeyPlayers:
• AbbVie Inc
• BASF SE
• Bayer AG
• Dr. Reddy’s Laboratories Ltd
• Eli Lilly and Company
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Pfizer Inc.
• SHIONOGI & Co. Ltd.
ViewFullReportwithTOC&ListofFigure:
https://www.imarcgroup.com/premenstrual-syndrome-treatment-market
We are the trusted business partners to the world's leading corporates, governments, and institutions
We are the trusted business partners to the world's leading corporates, governments, and institutions
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
